Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | CACNA1G | O43497 | 3/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15942971 | 0.89 | SIGMAR1 (0.57) | SIGMAR1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL798026 | 0.86 | MEN1 (0.56) | SIGMAR1HTR2AHTR2CCACNA1GKCNH2 | |
| SCHEMBL798078 | 0.85 | THRA (0.55) | SIGMAR1HTR2AHTR2CHTR7HTR6 | |
| SCHEMBL797736 | 0.81 | S1PR1 (0.54) | SIGMAR1 | |
| SCHEMBL25530952 | 0.78 | SIGMAR1 (0.61) | SIGMAR1KCNH2CACNA1IHRH3HRH1 | |
| SCHEMBL25531122 | 0.78 | SIGMAR1 (0.61) | SIGMAR1HTR2AHTR2CHTR7HRH3 | |
| SCHEMBL25541599 | 0.77 | SIGMAR1 (0.59) | SIGMAR1KCNH2CACNA1IHRH3 | |
| SCHEMBL12666612 | 0.77 | SIGMAR1 (0.78) | SIGMAR1HRH3 | |
| SCHEMBL25530980 | 0.76 | SIGMAR1 (0.62) | SIGMAR1HRH3HRH1 | |
| SCHEMBL25530974 | 0.76 | SIGMAR1 (0.74) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802663-B2 | Pyrazole oxadiazole derivatives as S1P1 agonists | MERCK SERONO SA (CH) | 2014-08-12 | — | — | US | disclosed |
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | MERCK SERONO SA (CH) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071460-A1 | PYRAZOLE OXADIAZOLE DERIVATIVES AS S1P1 AGONISTS | S1PR1, S1PR3, S1PR2 | SIGMAR1 501/4885HTR2A 1105/4885HTR2C 1098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.